WHAT ARE MARKERS?
And What Can They Tell Me About My Health?
Prostate cancer markers are making an impact on the world of prostate cancer by helping to individualize patient care in the early detection, diagnosis and treatment choices for prostate cancer. Through advanced science researchers from many different institutions and companies have developed a variety of tests that look at each persons genes or biomarkers and help to determine individual risk for having prostate cancer, the need for biopsies or repeat biopsies and often the best course of treatment.
Disease Identification And Diagnosis
One of the greatest challenges in prostate cancer care is identifying which cancers need treatment—and determining the most appropriate treatment plan for each patient. The U.S. Preventive Services Task Force has emphasized the importance of identifying measurable characteristics of prostate cancer that help predict poor health outcomes.
The Prostate Conditions Education Council (PCEC), in collaboration with scientists and diagnostic companies specializing in biomarkers and genomic testing, is working to close this gap. Together, we aim to provide tools that help patients and physicians make more informed decisions. This section highlights several established and emerging biomarkers our expert panel believes may significantly improve how prostate cancer is diagnosed and treated.
What Are Prostate Cancer Markers?
According to the National Cancer Institute, a prostate cancer marker is a biological molecule found in blood, tissue, or other body fluids that signals a normal or abnormal process—or the presence of disease. Markers may also include genetic mutations or DNA patterns in a tumor. Doctors use these tests to detect prostate cancer, assess its behavior, and guide treatment decisions.
Why Are Prostate Cancer Markers Important?
Prostate cancer markers play a critical role across the spectrum of care—from early detection to diagnosis and treatment planning. These tests help men better understand their individual risk and can distinguish between slow-growing and aggressive forms of the disease. By offering deeper insights into a tumor’s biology, they enable more personalized and effective care.
Improving Access!
Access to prostate cancer markers is improving nationwide. Many of these tests are now covered by Medicare and private insurance, and several testing companies also offer financial assistance programs to help reduce out-of-pocket costs.
If you have questions about test coverage or financial support options, don’t hesitate to contact us. We are here to help.
Scroll down to see what assessments are recommended for each of the following categories.
Screening and Early Detection
Who To Biopsy
Who to Treat
Who Would Benefit From Additional Treatment
Ongoing Testing
Genetic Testing
